AD
ADPT.US Adaptive Biotechnologies Corp
- Market cap
- USD 4.66B
- P/E
- -
- P/B
- 27.08x
- ROE
- -43.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ADPT.US undervalued?
Graham numberThe Graham number of Adaptive Biotechnologies Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Adaptive Biotechnologies Corp fundamental analysis
No fundamental analysis for Adaptive Biotechnologies Corp yet.
Adaptive Biotechnologies Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are …
Full company profileAdaptive Biotechnologies Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Adaptive Biotechnologies Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 38.4M | 55.7M | 85.1M | 98.4M | 154M | 185M | 170M | 179M | 277M | 302M |
| Gross Profit | 22.8M | 36.0M | 62.8M | 75.9M | 105M | 127M | 94.7M | 107M | 206M | 223M |
| Operating Income | -44.5M | -49.8M | -78.4M | -153M | -209M | -200M | -227M | -163M | -57.1M | -47.2M |
| EBITDA | -37.8M | -43.8M | -70.6M | -144M | -193M | -175M | -189M | -129M | -29.8M | -31.1M |
| Net Income | -42.8M | -46.4M | -68.6M | -146M | -207M | -200M | -225M | -159M | -59.5M | -75.9M |
| EPS | -0.41 | -0.44 | -0.55 | -1.11 | -1.48 | -1.40 | -1.56 | -1.08 | -0.39 | -0.41 |
| Balance Sheet | ||||||||||
| Total Assets | 362M | 333M | 912M | 1.12B | 923M | 857M | 661M | 539M | 513M | 683M |
| Total Liabilities | 587M | 591M | 341M | 373M | 319M | 393M | 353M | 337M | 288M | 499M |
| Shareholders' Equity | -225M | -258M | 571M | 743M | 604M | 464M | 308M | 203M | 219M | 176M |
| Cash & Short-term Investments | 192M | 165M | 577M | 688M | 353M | 498M | 346M | 222M | 227M | 299M |
| Total Debt | 562M | 561M | 36.6M | 108M | 112M | 108M | 98.8M | 89.4M | 281M | 409M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -34.9M | -32.3M | 205M | -150M | -193M | -184M | -156M | -95.2M | -46.0M | -8.44M |
| Capital Expenditure | 2.51M | 6.32M | 11.2M | 18.8M | 61.7M | 16.3M | 10.7M | 3.66M | 2.96M | 5.21M |
| Free Cash Flow | -37.4M | -38.6M | 194M | -168M | -254M | -200M | -167M | -98.9M | -48.9M | -13.7M |
| Ratios | ||||||||||
| ROE | - | - | -12.0% | -19.7% | -34.3% | -43.1% | -73.0% | -78.7% | -27.2% | -43.1% |
| ROA | -11.8% | -14.0% | -7.5% | -13.1% | -22.4% | -23.4% | -34.1% | -29.6% | -11.6% | -11.1% |
| Net Profit Margin | -111.4% | -83.4% | -80.6% | -148.6% | -134.3% | -108.0% | -132.3% | -89.1% | -21.5% | -25.2% |
| Debt to Equity | - | - | 0.06x | 0.15x | 0.19x | 0.23x | 0.32x | 0.44x | 1.28x | 2.32x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Adaptive Biotechnologies Corp dividends
Adaptive Biotechnologies Corp has not paid dividends in the last 9 fiscal years.
Last stock split: 1:4 on Jul 15, 2026.
Who owns Adaptive Biotechnologies Corp
- Insiders 1.27%
- Institutions 98.73%
- Public & others 0.00%
- Shares outstanding 162M
- Free float 128M
Top funds holding ADPT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 4.86M | 3.00% | +0.33% | Sep 2026 |
| iShares Russell 2000 ETF | 4.04M | 2.49% | 0.00% | Oct 2026 |
| ARK Genomic Revolution ETF | 1.91M | 1.18% | +0.58% | Oct 2026 |
| Vanguard Small Cap Index | 1.71M | 1.05% | -2.33% | Sep 2026 |
| Fidelity Small Cap Index | 1.69M | 1.04% | +0.13% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 1.50M | 0.93% | -0.38% | Oct 2026 |
| Alger Small Cap Focus I | 1.49M | 0.92% | 0.00% | Aug 2026 |
| T. Rowe Price New Horizons | 1.28M | 0.79% | +33.89% | Sep 2026 |
| Oberweis Micro-Cap | 1.22M | 0.75% | +56.93% | Jun 2026 |
| iShares Biotechnology ETF | 1.21M | 0.75% | -0.19% | Oct 2026 |
| T. Rowe Price Small-Cap Stock | 1.17M | 0.73% | -0.57% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 1.16M | 0.72% | +0.27% | Oct 2026 |
| Lord Abbett Developing Growth A | 1.15M | 0.71% | -3.73% | Aug 2026 |
| Invesco Main Street Small Cap R6 | 1.12M | 0.69% | 0.00% | Sep 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 1.10M | 0.68% | 0.00% | Sep 2026 |
| BNP Paribas US Small Cap ClassicC | 976K | 0.60% | -8.50% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 950K | 0.59% | -5.10% | Sep 2026 |
| BNP Paribas Health Cr Innovtr Cl Cap | 949K | 0.59% | -6.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 925K | 0.57% | +4.46% | Sep 2026 |
| Vanguard Explorer Inv | 895K | 0.55% | -9.94% | Sep 2026 |
Top institutions holding ADPT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Viking Global Investors LP | 30.0M | 18.53% | 0.00% | Jun 2026 |
| BlackRock Inc | 15.1M | 9.35% | +13.80% | Jun 2026 |
| Vanguard Capital Management, LLC | 6.40M | 3.96% | +5.08% | Jun 2026 |
| Wellington Management Company LLP | 5.91M | 3.65% | +53.25% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 5.48M | 3.38% | +21.93% | Jun 2026 |
| D. E. Shaw & Co LP | 4.63M | 2.86% | +135.34% | Jun 2026 |
| Westfield Capital Management Company, L.P. | 4.27M | 2.64% | -21.50% | Jun 2026 |
| Geode Capital Management, LLC | 3.64M | 2.25% | +0.16% | Jun 2026 |
| State Street Corp | 3.46M | 2.14% | +7.16% | Jun 2026 |
| Amvescap Plc. | 3.09M | 1.91% | -30.47% | Jun 2026 |
| The Goldman Sachs Group Inc | 2.98M | 1.84% | -7.95% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 2.67M | 1.65% | +70.18% | Jun 2026 |
| Driehaus Capital Management LLC | 2.53M | 1.56% | +44.39% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 2.52M | 1.56% | +26.53% | Jun 2026 |
| Lord, Abbett & Co LLC | 2.47M | 1.53% | -30.01% | Jun 2026 |
| Principal Financial Group Inc | 2.45M | 1.51% | +6,198.61% | Sep 2026 |
| Nuveen, LLC | 2.37M | 1.46% | +81.43% | Jun 2026 |
| BNP Paribas Investment Partners SA | 2.18M | 1.35% | -18.81% | Jun 2026 |
| Fred Alger Management, LLC | 2.09M | 1.29% | +1.41% | Jun 2026 |
| ARK Investment Management LLC | 2.09M | 1.29% | -0.13% | Jun 2026 |
Adaptive Biotechnologies Corp company profile
- Company name
- Adaptive Biotechnologies Corp
- Ticker
- ADPT.US
- Exchange
- USA Stocks
- Listed since
- Jun 27, 2019
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 624
- Fiscal year end
- December
- Address
- 1165 Eastlake Avenue East, Seattle, WA, United States, 98109
- Phone
- 206 659 0067
- Website
- adaptivebiotech.com
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Adaptive Biotechnologies Corp management
10- Mr. Chad M. Robins M.B.A.Co-Founder, CEO & Chairman · born 1975
- Ms. Julie RubinsteinPresident & COO · born 1972
- Mr. Kyle PiskelVP, CFO & Principal Accounting Officer · born 1984
- Ms. Susan BobulskyChief Commercial Officer of MRD · born 1981
- Mr. Christopher Carlson Ph.D.Founder
- Ms. Karina CalzadillaVP of Investor Relations and FP&A
- Ms. Clarice McCauleyHead of Legal, Corporate Secretary, VP & Chief Compliance Officer
- Mr. Francis T. LoChief People Officer · born 1981
- Dr. Sharon Benzeno Ph.D.Chief Commercial Officer of Immune Medicine · born 1974
- Ms. Mary Pat LancelottaSenior Vice President, Global Market & Business Development